Hims & Hers Launches Five Unapproved Peptides, Admits Efficacy Is Unclear
The telehealth company is now selling compounded sermorelin, glutathione, NAD+, B-12 and L-carnitine, none FDA-approved, betting consumer demand outruns the evidence.

Hims & Hers has launched compounded sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are FDA-approved, while publicly conceding there is more to learn about their efficacy. For telehealth operators and their boards, the move tests how far the compounding gray zone can stretch before regulators, payers, or consumers push back.
Hims & Hers just put five new treatments on the shelf, and it is telling customers up front that the science is still catching up. The telehealth company is now offering compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, and none of the five is approved by the Food and Drug Administration. The company is also acknowledging that there is more to learn about efficacy. A product launch and a public shrug, delivered in the same breath, is the part worth pausing on.
The word doing the heavy lifting here is "compounded." It means these are versions prepared by compounding pharmacies rather than branded drugs that cleared the FDA's approval process. That distinction matters. FDA approval typically requires clinical trials that demonstrate a drug is safe and effective for a specific use, a bar that regularly takes years and hundreds of millions of dollars to clear. Compounded drugs travel a different road, made for individual patients under a patchwork of federal and state compounding rules. None of the five compounds Hims & Hers is now offering has walked the approval path.
The names on the list are familiar to anyone who spends time in the wellness and longevity aisle. Sermorelin is typically discussed as a growth-hormone-related peptide. Glutathione and NAD+ are staples of the drip-and-infusion circuit. Vitamin B-12 and L-carnitine show up constantly in energy, recovery, and performance marketing. Together they form a bundle aimed at the same customer who already buys into the broader optimization category, and bundling is the point. Telehealth economics run on subscriptions, and subscriptions run on repeat demand. Five products give a customer five reasons to stay, and give the platform five hooks for the next upsell.
That is also exactly why the regulatory question is not a footnote. Historically, the FDA has moved to tighten the list of bulk drug substances compounders are permitted to use, and state pharmacy boards write their own rules on top of that. The gray zone is not a permanent address; it is weather. A company can build a real business inside it, and then watch a single regulatory decision redraw the shelf overnight. Executives who treat compounding as a loophole rather than a standing risk are one rule change away from explaining a revenue hole to their board.
The candor about efficacy is the more interesting strategic choice. Companies rarely ship a product while flagging uncertainty about whether it works. Read generously, it is expectation management and legal hygiene: say plainly what the evidence does not yet show, and you blunt the argument that you oversold. Read skeptically, it is an admission that the demand curve got there before the data did. Either way, the customer hears the same thing, which is that the buyer is participating in the experiment rather than receiving a proven therapy. In a category where placebo effects are strong and dosing is loose, that sentence carries real weight.
For context, this is the second act of a pattern that has defined consumer telehealth for several years. Platforms built massive audiences by moving faster than the traditional pharmaceutical pipeline, offering compounded alternatives in categories where demand was loud and supply was constrained. That strategy works beautifully until regulators, litigators, or state boards decide the math has changed. Hims & Hers is publicly traded, which means the compounding exposure is not just a clinical question, it is a disclosure question. Investors will want to know how much of the recurring revenue base sits on unapproved formulations and what happens to retention if any of the five disappears.
There are second-order effects across the sector. Peers watching this launch face a competitive squeeze: match the portfolio and inherit the same regulatory risk, or hold back and cede a fast-growing category to whoever moves first. Pharmacy partners carry their own liability and their own state licensing exposure. And the physicians and nurse practitioners writing these orders are the ones holding the clinical relationship when a patient asks whether the treatment works. The platform's language about efficacy becomes the clinician's problem at the point of care.
The strategic takeaway for boards is not that compounded wellness products are inherently bad. It is that speed-to-market in a gray zone is a financing decision as much as a product decision. What is the downside scenario if the FDA restricts a compound? How concentrated is the revenue? What does the marketing say versus what the label can claim? Hims & Hers has answered the first half of that question out loud, and that is rarer than it should be. The second half, what happens if the rules move, is the part every operator in this category should be stress-testing now.
This story's Key Insights and Take-aways are locked.
Create a free account to unlock Executive Actions for one credit.
Register to UnlockAlways free for Executives Club members. Join the Club
More in Business
S&P 500 Enters Correction, Down 10% From Its High on AI Worries
The index's slide past the 10 percent line is a symbolic verdict on investor mood, and the AI trade that powered the rally is now the thing testing it.
Dow and S&P 500 enter correction as Nasdaq logs worst week since 2020
All 11 S&P 500 sectors fell more than 1% in the same week for the first time since April 2025, a breadth signal that matters more than any single index level.
Chip stocks lose $2.3 trillion in a week, worst run in 25 years
A $2.3 trillion weekly wipeout in semiconductors is forcing every board with an AI story to ask whether it owns a thesis or just a crowded trade.



